Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Sandham

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
ACS Medicinal Chemistry Letters|September 27, 2017
Correction to "Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP<sub>2</sub> Receptor Antagonist for Treatment of Asthma"David A Sandham, Lucy Barker, Lyndon Brown, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2007
2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonistsDavid A Sandham, Clive Aldcroft, Urs Baettig, et al.
ACS Medicinal Chemistry Letters|May 20, 2017
Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP<sub>2</sub> Receptor Antagonist for Treatment of AsthmaDavid A Sandham, Lucy Barker, Lyndon Brown, et al.
Bioorganic & Medicinal Chemistry Letters|March 6, 2007
Potent and selective xanthine-based inhibitors of phosphodiesterase 5Nichola J Arnold, Ruth Arnold, David Beer, et al.
Bioorganic & Medicinal Chemistry|September 8, 2004
Synthesis and biological properties of novel glucocorticoid androstene C-17 furoate estersDavid A Sandham, Lucy Barker, David Beattie, et al.
Bioorganic & Medicinal Chemistry|September 12, 2013
Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseasesDavid A Sandham, Nicola Arnold, Heinrich Aschauer, et al.
Journal of Medicinal Chemistry|February 17, 2025
Discovery of GJG057, a Potent and Highly Selective Inhibitor of Leukotriene C4 SynthaseGebhard Thoma, Wolfgang Miltz, Rudolf Waelchli, et al.
Journal of Medicinal Chemistry|May 24, 2021
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary DiseaseDarren Le Grand, Martin Gosling, Urs Baettig, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
ACS Medicinal Chemistry Letters|September 27, 2017
Correction to "Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP<sub>2</sub> Receptor Antagonist for Treatment of Asthma"David A Sandham, Lucy Barker, Lyndon Brown, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2007
2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonistsDavid A Sandham, Clive Aldcroft, Urs Baettig, et al.
ACS Medicinal Chemistry Letters|May 20, 2017
Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP<sub>2</sub> Receptor Antagonist for Treatment of AsthmaDavid A Sandham, Lucy Barker, Lyndon Brown, et al.
Bioorganic & Medicinal Chemistry Letters|March 6, 2007
Potent and selective xanthine-based inhibitors of phosphodiesterase 5Nichola J Arnold, Ruth Arnold, David Beer, et al.
Bioorganic & Medicinal Chemistry|September 8, 2004
Synthesis and biological properties of novel glucocorticoid androstene C-17 furoate estersDavid A Sandham, Lucy Barker, David Beattie, et al.
Bioorganic & Medicinal Chemistry|September 12, 2013
Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseasesDavid A Sandham, Nicola Arnold, Heinrich Aschauer, et al.
Journal of Medicinal Chemistry|February 17, 2025
Discovery of GJG057, a Potent and Highly Selective Inhibitor of Leukotriene C4 SynthaseGebhard Thoma, Wolfgang Miltz, Rudolf Waelchli, et al.
Journal of Medicinal Chemistry|May 24, 2021
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary DiseaseDarren Le Grand, Martin Gosling, Urs Baettig, et al.
Pageof 7